The Invisible Achievement: Why Universities Still Don't Know How to Celebrate a Spinout
A researcher can found a company, license a technology to a global manufacturer, and generate millions in institutional revenue — and still face a promotion committee that wants to know why their publication count slipped.
In 2018, a materials scientist at a German technical university co-founded a spinout based on a novel battery electrode technology he had developed over five years. Within three years the company had raised €8 million in Series A funding, employed fourteen people, signed a development agreement with a major automotive supplier, and generated licensing revenue that contributed directly to the university's research budget. When his department conducted its annual performance review that year, the committee noted, approvingly, that he had published four papers. The spinout was listed under "other activities." It carried no formal weight in the assessment of his academic standing. He was passed over for a full professorship in favour of a colleague with a longer publication list and no commercial activity. He left the university eighteen months later.
His departure was not a personal failure. It was a system operating exactly as designed — a design that has remained substantially unchanged since the modern research university took its current form in the early twentieth century, even though almost everything else about the relationship between universities and the economy has transformed around it. The failure to recognise commercialisation as a legitimate and valued form of academic achievement is not a gap the university has simply forgotten to close. It is a gap that the university has, in many cases, actively chosen to maintain — and understanding why reveals something important about how institutions preserve their own identity at the cost of their own stated mission.
The architecture of academic recognition was built around a single, elegant logic: scientific achievement is what peers say it is, and peer judgment is expressed through publication in refereed journals and election to positions of institutional authority. The h-index, the journal impact factor, the citation count — these instruments were developed to make peer judgment legible and comparable across institutions. They were not designed to capture value created outside the academic system. They cannot, by construction, do so.
The commercialisation mandates that arrived in the 1980s and 1990s created an institutional obligation to pursue spinouts, licences, and industry partnerships without touching the recognition structures that determined whose career advanced. Universities created technology transfer offices, established innovation funds, and issued strategy documents proclaiming their commitment to economic impact. They did not, in any systematic way, revise their promotion criteria, their tenure clocks, or their performance review frameworks to reflect the new expectation. The result was a generation of researchers told simultaneously that commercialisation mattered and that it would not be rewarded — a contradiction that most resolved, rationally, by treating commercialisation as an extracurricular activity pursued at personal risk after the publication requirements were met.
A 2022 survey of 1,800 academics across fifteen European countries, published in Science and Public Policy, found that only 18% worked at institutions where patents or licences carried formal weight in promotion decisions, and fewer than 10% at institutions where spinout founding was explicitly recognised in tenure review. An analysis of promotion criteria at the top 50 European research universities found that 94% listed publication record as a primary criterion and fewer than 20% included any commercialisation metric. A longitudinal study tracking researcher behaviour following successful spinout exits found that the majority of academic founders reported no change in their institutional standing as a result.
The scepticism is culturally embedded and professionally transmitted. Senior academics who have built distinguished careers entirely within the publication-and-grant paradigm are, inevitably, the people who sit on promotion committees and shape departmental norms. Their judgment of what constitutes serious academic work reflects, naturally, the activities through which they themselves achieved distinction. A full professor who has never founded a company, negotiated a licence, or spoken to a venture capitalist is not well-positioned to assess the difficulty or significance of doing so — and the institutional framework gives them no reason to try.
"I have a company that makes a product that people use. I have a colleague who has published forty-seven papers that nobody reads. We are evaluated by the same criteria, and by those criteria, he is more productive than I am. I find it very difficult to explain this to my students."
— Associate professor and spinout founder, TU Eindhoven, 2024The consequences accumulate at every level of the research system. At the individual level, researchers who have invested years in commercialisation activity carry a specific professional anxiety that their publication-focused peers do not: the knowledge that their most significant professional achievements may not be legible to the people who decide their careers. The patent that took three years to develop and generated substantial licensing revenue does not appear on a CV in the same way a Nature paper does. The spinout that employs twenty people and is on a trajectory to Series B does not generate the kind of peer recognition that a high-citation publication does. The work was real. The system for acknowledging it was not built for it.
At the institutional level, the recognition gap creates a selection effect over time. Researchers who prioritise commercialisation are the researchers most likely to leave academic positions for industry or for the institutions that have begun to recognise their contribution differently. The universities that do not adapt lose precisely the researchers most capable of generating the economic impact they claim to prioritise.
"The university celebrated our licensing deal in a press release. Nobody mentioned it at my review. I have learned to understand the difference between what institutions say they value and what they actually reward."
There is also a visibility problem that operates before any question of institutional recognition arises. The researcher whose commercialisation achievements are genuinely significant is often unable to communicate those achievements effectively to the audiences that could act on them. Academic CVs are not built to showcase commercial milestones. University profiles do not routinely highlight licensing revenues or spinout valuations. The researcher who has done genuinely important commercial work is, in many cases, invisible to both the institution that employs them and the market that could recognise them.
Making achievements visible — to the university and to the market simultaneously — is not simply a matter of better record-keeping. It requires an active effort to translate commercial accomplishments into the languages that different audiences understand and value. For the institution, that means documenting patents, spinout formation, licensing income, and industry partnerships in terms that connect to the university's own stated strategic priorities — impact agendas, knowledge exchange metrics, research commercialisation targets — and presenting them in formats that promotion committees can evaluate alongside publication records. For the market, it means building a professional presence that makes the researcher's commercial track record legible to investors, partners, and acquirers.
Patents, spinouts, and licensing income are not niche accomplishments. They are, for a growing number of researchers, the most significant contributions of their careers. They deserve to be seen — by the university that claims to value them, and by the market that is prepared to act on them. The researcher who built the battery company, or licensed the filtration system, or co-developed the diagnostic platform is not asking for special treatment. They are asking for the same thing their publication-focused colleagues receive as a matter of course: the acknowledgement that the work was real, that it mattered, and that the institution they gave their most productive years to noticed.